世界初のhead-to-head試験のサブ解析で、アビラテロンの転移なし去勢抵抗性前立腺癌への妥当性が示唆される内容です。

Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.

Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A.

Cancers (Basel). 2024 Jan 24;16(3):508. doi: 10.3390/cancers16030508.